Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

Joanna L. Siegel, Roberta Jorgensen, Paul Angulo, Keith Lindor

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug. Goals: We compared weight changes in patients treated with UDCA and those on placebo to characterize this potential side effect. Study: One-hundred eighty patients with PBC who were enrolled into a randomized, controlled trial received either UDCA (13-15 mg/kg/d) or an identical placebo. Changes from baseline weight were calculated at 12, 24, 36, and 48 months. Other markers of disease activity, including liver biochemistries, serum lipids, histologic stage, and Mayo Risk Score were evaluated in both groups. Results: The proportion of patients who gained weight during the first 12 months of therapy was significantly greater in the UDCA than placebo group (67/86 [78%] versus 43/73 [57%] respectively, P = 0.005). Patients in the UDCA group gained an average of 3.6 ± 6.5% kg (2.2 ± 5.1 kg) which was significantly greater than the average of 0.6 ± 6.9% kg (0.6 ± 4.9 kg) gained in the placebo group (P = 0.04). The biggest change in weight occurred in the first 12 months of treatment (P < 0.001); after this, weight was maintained for the 4-year duration of treatment. There was no significant correlation between initial body mass index (BMI) and weight change or changes in disease activity and weight. Conclusion: UDCA treatment in patients with PBC is associated with a significant weight gain that occurs in the first 12 months of treatment, persists for the duration of treatment, and occurs independent of baseline BMI. Discussions with PBC patients beginning UDCA treatment should include the beneficial effects this medication has on disease outcome, but should also mention weight gain as a possible side effect.

Original languageEnglish (US)
Pages (from-to)183-185
Number of pages3
JournalJournal of Clinical Gastroenterology
Volume37
Issue number2
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Weight Gain
Weights and Measures
Placebos
Therapeutics
Body Mass Index
Biochemistry
Randomized Controlled Trials
Lipids
Liver

Keywords

  • Primary biliary cirrhosis
  • Ursodeoxycholic acid
  • Weight gain

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. / Siegel, Joanna L.; Jorgensen, Roberta; Angulo, Paul; Lindor, Keith.

In: Journal of Clinical Gastroenterology, Vol. 37, No. 2, 08.2003, p. 183-185.

Research output: Contribution to journalArticle

@article{ff5daf96d0a04b20a608f4c4bcb10150,
title = "Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis",
abstract = "Background: Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug. Goals: We compared weight changes in patients treated with UDCA and those on placebo to characterize this potential side effect. Study: One-hundred eighty patients with PBC who were enrolled into a randomized, controlled trial received either UDCA (13-15 mg/kg/d) or an identical placebo. Changes from baseline weight were calculated at 12, 24, 36, and 48 months. Other markers of disease activity, including liver biochemistries, serum lipids, histologic stage, and Mayo Risk Score were evaluated in both groups. Results: The proportion of patients who gained weight during the first 12 months of therapy was significantly greater in the UDCA than placebo group (67/86 [78{\%}] versus 43/73 [57{\%}] respectively, P = 0.005). Patients in the UDCA group gained an average of 3.6 ± 6.5{\%} kg (2.2 ± 5.1 kg) which was significantly greater than the average of 0.6 ± 6.9{\%} kg (0.6 ± 4.9 kg) gained in the placebo group (P = 0.04). The biggest change in weight occurred in the first 12 months of treatment (P < 0.001); after this, weight was maintained for the 4-year duration of treatment. There was no significant correlation between initial body mass index (BMI) and weight change or changes in disease activity and weight. Conclusion: UDCA treatment in patients with PBC is associated with a significant weight gain that occurs in the first 12 months of treatment, persists for the duration of treatment, and occurs independent of baseline BMI. Discussions with PBC patients beginning UDCA treatment should include the beneficial effects this medication has on disease outcome, but should also mention weight gain as a possible side effect.",
keywords = "Primary biliary cirrhosis, Ursodeoxycholic acid, Weight gain",
author = "Siegel, {Joanna L.} and Roberta Jorgensen and Paul Angulo and Keith Lindor",
year = "2003",
month = "8",
doi = "10.1097/00004836-200308000-00018",
language = "English (US)",
volume = "37",
pages = "183--185",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

AU - Siegel, Joanna L.

AU - Jorgensen, Roberta

AU - Angulo, Paul

AU - Lindor, Keith

PY - 2003/8

Y1 - 2003/8

N2 - Background: Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug. Goals: We compared weight changes in patients treated with UDCA and those on placebo to characterize this potential side effect. Study: One-hundred eighty patients with PBC who were enrolled into a randomized, controlled trial received either UDCA (13-15 mg/kg/d) or an identical placebo. Changes from baseline weight were calculated at 12, 24, 36, and 48 months. Other markers of disease activity, including liver biochemistries, serum lipids, histologic stage, and Mayo Risk Score were evaluated in both groups. Results: The proportion of patients who gained weight during the first 12 months of therapy was significantly greater in the UDCA than placebo group (67/86 [78%] versus 43/73 [57%] respectively, P = 0.005). Patients in the UDCA group gained an average of 3.6 ± 6.5% kg (2.2 ± 5.1 kg) which was significantly greater than the average of 0.6 ± 6.9% kg (0.6 ± 4.9 kg) gained in the placebo group (P = 0.04). The biggest change in weight occurred in the first 12 months of treatment (P < 0.001); after this, weight was maintained for the 4-year duration of treatment. There was no significant correlation between initial body mass index (BMI) and weight change or changes in disease activity and weight. Conclusion: UDCA treatment in patients with PBC is associated with a significant weight gain that occurs in the first 12 months of treatment, persists for the duration of treatment, and occurs independent of baseline BMI. Discussions with PBC patients beginning UDCA treatment should include the beneficial effects this medication has on disease outcome, but should also mention weight gain as a possible side effect.

AB - Background: Ursodeoxycholic acid (UDCA) is the established treatment of primary biliary cirrhosis (PBC) and is a safe and well-tolerated medication. Nevertheless, patients often anecdotally complain of weight gain while on this drug. Goals: We compared weight changes in patients treated with UDCA and those on placebo to characterize this potential side effect. Study: One-hundred eighty patients with PBC who were enrolled into a randomized, controlled trial received either UDCA (13-15 mg/kg/d) or an identical placebo. Changes from baseline weight were calculated at 12, 24, 36, and 48 months. Other markers of disease activity, including liver biochemistries, serum lipids, histologic stage, and Mayo Risk Score were evaluated in both groups. Results: The proportion of patients who gained weight during the first 12 months of therapy was significantly greater in the UDCA than placebo group (67/86 [78%] versus 43/73 [57%] respectively, P = 0.005). Patients in the UDCA group gained an average of 3.6 ± 6.5% kg (2.2 ± 5.1 kg) which was significantly greater than the average of 0.6 ± 6.9% kg (0.6 ± 4.9 kg) gained in the placebo group (P = 0.04). The biggest change in weight occurred in the first 12 months of treatment (P < 0.001); after this, weight was maintained for the 4-year duration of treatment. There was no significant correlation between initial body mass index (BMI) and weight change or changes in disease activity and weight. Conclusion: UDCA treatment in patients with PBC is associated with a significant weight gain that occurs in the first 12 months of treatment, persists for the duration of treatment, and occurs independent of baseline BMI. Discussions with PBC patients beginning UDCA treatment should include the beneficial effects this medication has on disease outcome, but should also mention weight gain as a possible side effect.

KW - Primary biliary cirrhosis

KW - Ursodeoxycholic acid

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=0038044776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038044776&partnerID=8YFLogxK

U2 - 10.1097/00004836-200308000-00018

DO - 10.1097/00004836-200308000-00018

M3 - Article

VL - 37

SP - 183

EP - 185

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 2

ER -